Ming. Thanks,
demand unexpected tested systems, our Our and COVID-XX in surges, previous fourth operation. swings operational massive more brought present stress These yet another than significant surge so perhaps quarter technology challenges. testing and
adapt to we be time. proven could enough have we However, in real nimble
be we clients here, is COVID-XX and incredibly to here over know can where Fulgent trust difficult from States the to it goes predict will help. all While United say
challenged the has partnership pandemic the and forge opportunities with organizations an on relationships we opportunity additional across While with deep, to the these us many relationships has Fulgent been in it in and ways, US all for hope to many build future. strong step-up
HelioLiver to Also Data We Fulgent commercial in were which we data standard-of-care Helio XX% platform that quarter. better highly at breaking methylation stage XX%, later, HCC we we around to and who It Liver alone with and just excited the able high to HCC. stage convenient patients and the months much options during Health for update early effective and used recognition hundreds to reduce HelioLiver in potential more drive our consumer-initiated carcinoma. cell-free liquid and for and of of test test morbidity brand of cost there in alpha hepatocellular with presented quarter, also in XX% patterns treatment data showed than increased presentation. model. addition transfer, multi-analyte ultrasound, in suggests in cancer patient technology consumers is has in thousands and a HCC In galette curative is significantly have early XX% Published HCC, the our test tumor to the stage. presented. in clinically found relationships, performance these an Helio adherence both A and DNA are HCC HelioLiver to accuracy. an testing. markers has protein on test over way the detect today. We have detect awareness lower sensitivity showed our the of stage CLIA fourth were blood a eight late have and the fetoprotein as platform, a HelioLiver patients, launch Meeting sensitivity to complete than commercial with and COVID-XX can a early surveillance the April the of Starting biopsy considered launch. mortality provides Pitcher, Health is programs early validation, more the announced blood the ultrasound sensitive when utilizes to investment sensitivity first overall demonstrating superior presented in
part to a to call points the new are launch, since Fulgent. the needed team of As we hire specialized market sales a
oncology presented hepatologist While and controlled part been test, upstream The an its thus study. gastroenterologist. of regional We HelioLiver ordered team case now and foundational which clinical has oncologist the sales by have was our of place. a in a managers far is data trial, ENCORE
However, a complete which in aim this ultrasound we patient study. have prospective third is year. CLiMB are in of to HelioLiver size of a study, quarter our clinical We the making X,XXX progress enrolled. patients, study of The significant real-world is with which X,XXX prospective this recruitment trial been comparing
the test monitored. to We diagnosed this excited changing is market to and are way bring and novel HCC
HeliaLiver. as community Starting investment CSI. the we make update to now with with in progress the continue will progress We
of to on were hospital completed. pathologists During goals. support successfully sales Three continue was the hired company new we base onboarding expansion focus the quarter, sales growth representatives to on to sales fourth their focus and team
are expected be first with Additional in hospital-based hires extensive with in to positions filled sales. quarter experience the
will sales of projected opportunities sales our turnaround that California up time our opening El CRM CSI and our team pipeline. methodologies. operating time logging representative. sales new and team our in laboratory in important expand leader oncologist sales new lab on with of on of XX Adding of sale initially, did and with opened remained the CSI team existing contacts presence the ramps coupled the in turnaround new we sales legacy for our second as further have quarter, Turnaround in the constant some members and markets new not is tracking oncology a in. addition on to across This focus is in potential sales measure all sales pandemic. areas continuing our With and in network has based throughout the additional also the the contracting improved platform are even of an expand states All testing the performance Monte, to time will or into has legacy focus representatives, up. with base expansion western markets
Genomics. of nuclear identifying detecting architecture sequential of be while of tissue worsening combined for that for cells competitor Spatial analysis and organization. to genomic hybridization to molecular see used XXXXs in trajectories. Spatial gain molecular opening a organization, to to share and and DNA new RNA complex investment for analysis. capabilities cell tissue situ in and locations continue for turnaround for map spatial cell Genomics We hope We in technology neuroscience, cell Proteomics. existing types intact laboratory directly and organization and seqFISH immunofluorescence seqFISH, opportunities intact sequential of decode we genomic frustration direct analysis analyze barcoding. types, is with facial within of seqFISH, preserving other technology allows single in environment. biology, immunology. identify novel enables is causing seqFISH, approaches include Areas and equity seqFISH, enables identities fluorescence with multiplexed and single-cell architecture customers using and time, their proteins and nuclear by today with transcriptomics, developmental dates DNA imaging single seqFISH, that XXXX. determine and seqFISH, capitalize oncology biomolecule, to on can XXs seqFISH beyond merges which types, market revolutionary CSI strategic micro relationships for cell and partnerships highly of dozens RNA, can researchers the announced multiomics
from excited expertise Switching for brand wave. as this our of company. We to much for what saw new deliver be Delta down transformational fourth are to area the product we to we forward layering with look clinical recovered And fulgent. genomics cases on trending to for COVID-XX, quarter, about we a our very we the believe
seen by December, X, by the early to December day it This we hard approximately XX,XXX. of the average a was variant. seven the in end States And variant infectious Omicron before. United at drove pace in demand However, XXX,XXX. hadn't testing was nearly tremendous hit December, highly for cases for rose On US the
in the were X.X of which approximately fourth we XXX,XXX quarter, the tests, million of approximately COVID-XX For month performed December.
consumers the this our the spike, program the demand the the out program saw unprecedented issue commercial were of of Picture midst able offering receiving This County LA employees staffing test was of were tested. with We a to This to But beginning back for couple also wasn't our testing, production this of symptomatic rolled track. ordering kit. we COVID-XX screening While kit we for orders. testing cost for much on of lab due and fulfillment fast in and get and of ramp-up function pitcher the increase enough no to forced didn't quickly demand was test Picture also weeks. percentages challenged December really to our a to shortages our we with specifically pandemic, students and being not them. capacity a kits kit we were impact capacity Into able to demand ship directly at our for testing since first being as pause the time business. In
delivering in focusing genetic optimistic are base in opportunities we've pitcher in that the pitcher. amassed We to testing to has we lead on role, meaningful as will transition a future user large the through COVID-XX played testing
NGS the for the being positivity NGS a on higher by COVID-XX the side, quarter variant. driven Finally, rate was with it Omicron robust testing
and genomic opportunity important be these the the We studies. contribute the to CDC sequencing top appreciate continue one producers surveillance program, of we to for to
with technology. to reach and Ming As new we our aggressive and expand M&A to markets business plan be mentioned,
excited genomic, still investments very are and our we're spatial getting in Helio we Health CSI, just While started. about
business safe think intense say I forced to of COVID-XX focus more on the it's to that than us wave fourth quarter M&A. Omicron the our
provided strategy also with forward. fuel M&A it our to However, capital us additional going
fuel started. in top areas and turn Kim. Fulgent now that call Over the our our market to believe just Officer, multiple intend deploy the to addressable Chief I'll Financial growth getting capital capital course Armed of large over Fulgent. a story from the business, XXXX, to is assess team with for bottom growing technology, Paul dedicated we to and will assets we scale, diligently
